Fischer, S. and Zechmeister-Koss, I. (2014): Vasoprotectives: Efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoidal diseases. HTA-Projektbericht 79.

Fried, A. (2007): [The pharmaceutical industry puts pressure on publishers]. HTA-Newsletter 53: p. 1.

Gregor-Patera, N. (2023): Sponsoring of patient initiatives in Austria. 5th Update of the Systematic Analyses 2014 to 2019. AIHTA Policy Brief 007/ 5. Update.

Gregor-Patera, N. and Petersen, P. and Wild, C. (2017): Sponsoring of Patient Initiatives in Austria 2016. Update of the Systematic Analyses 2015 and 2014. Rapid Assessment 007b_2. Update 2017.

Mad, P. and Geiger-Gritsch, S. and Mittermayr, T. and Wild, C. (2009): Tocolysis in preterm labour - A systematic review of evidence-based guidelines, effectiveness and health economic evaluations. HTA-Projektbericht 030.

Mantsch, S. and Petersen, P. and Wild, C. (2016): Pharma: Disclosure of payments in Austria 2015. Rapid Assessment 007d.

Petersen, P. and Wild, C. (2017): Sponsoring of Patientinitiatives in Austria 2015. Update of the Systematic Analysis 2014.. Rapid Assessment 007b_1. Update 2017.

Sehic, O. (2021): Sponsoring of patient initiatives in Austria. Update of the Systematic Analyses 2014 to 2018. AIHTA Policy Brief 007.

Sehic, O. (2019): Pharma: Disclosure of transfers of value in Austria 2018. Update of the systematic analysis 2015. Rapid Assessment 007d_1. Update 2019.

Wild, C and Wolf, S and Goetz, G and Walter, M and McEntee, J and Stanak, M and Ettinger, S and Strohmaier, C and Erdos, J and Huić, M (2020): Covid-19: HSS/ Horizon Scanning Living Document. AIHTA Policy Brief 002.

Wild, C. and Fabian, D. (2024): The Role of Public Contributions to the Development of Health Innovations. HTA-Projektbericht 158.

Wild, C. (2007): [Biosimilars]. HTA-Newsletter 54: p. 2.

Wild, C. (2004): [The Oregon drug class review project as initiative for generics]. ITA-Newsletter September 2004: p. 13.

Wild, C. (2004): [The Oregon drug class review project as initiative for generics. Editorial]. HTA-Newsletter 28: p. 1.

Wild, C. (2004): [Transparency in the pharmaceutical industry. Editorial]. HTA-Newsletter 25: pp. 1-2.

Wild, C. (2003): [Guidance for manufacturers and medical associations on submission of evidence]. ITA-Newsletter December 2003: p. 9.

Wild, C. (2002): [Guidance for manufacturers and medical associations on submission of evidence]. ITA-Newsletter September 2002: p. 11.

Wild, C. (2002): [Guidelines for manufacturers and medical associations on submission of evidence. Editorial]. HTA-Newsletter 08: p. 1.

Wild, C. (2001): [Project on generics: Saving 5 million schilling]. ITA-Newsletter December 2001: p. 10.

Wild, C. (2001): [Innovations and (expensive) followers]. ITA-Newsletter December 2001: p. 9.

Wild, C. (2001): [Generics and cost reduction: A project in Austria]. HTA-Newsletter 02: p. 4.

Wild, C. (2006): [Generics vs. brand name drugs after patent expiration] . ÖKZ: Österreichische Krankenhauszeitung 47 (10): p. 16.

Wild, C. (2001): [Approval of innovative drugs]. ORF ON Science.

Wild, C. and Khan, A. and Erdos, J. (2015): Sponsoring of Patient Initiatives in Austria. Systematic Analysis. Rapid Assessment 007b.

Wolf, S. and Wild, C. (2018): Drug reimbursement in the inpatient sector in Austria: Approaches for a transparent and evidence-based process, taking into account international experience . HTA-Projektbericht 109.